<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613621</url>
  </required_header>
  <id_info>
    <org_study_id>T4222</org_study_id>
    <nct_id>NCT05613621</nct_id>
  </id_info>
  <brief_title>Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies</brief_title>
  <acronym>T4222</acronym>
  <official_title>Dissection of the Molecular and Immunological Interaction in Patients With Hepatocellular Carcinoma of Viral and Non-viral Etiologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will clarify the potential interaction between HBV infection and steatosis, and&#xD;
      their impact on genetic alterations and tumor immune microenvironment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will start with a &quot;training cohort&quot; of the NTUH and NTU Cancer Center patients,&#xD;
      consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis&#xD;
      (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-)&#xD;
      anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by&#xD;
      histology. We will enroll 400 patients who had sufficient tissue for testing in the training&#xD;
      cohort. The following studies will be performed: (1) NGS of targeted genes panel using the&#xD;
      National Health Research Institutes precision medicine platform; (2) transcriptomic analysis&#xD;
      of immune microenvironment using RNA-seq and multiplex immunofluorescence staining; (3)&#xD;
      lipotoxic genotyping for SNPs; (4) clinical outcomes of MAFLD vs. non-MAFLD. The genetic and&#xD;
      immunological features will be further tested by a &quot;validation cohort&quot;, from collaborative&#xD;
      hospitals. This project will clarify the potential interaction between HBV infection and&#xD;
      steatosis, and their impact on genetic alterations and tumor immune microenvironment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>transcriptomic analysis of immune microenvironment</measure>
    <time_frame>2 Years</time_frame>
    <description>using RNA-seq and multiplex immunofluorescence staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lipotoxic genotyping for SNPs</measure>
    <time_frame>2 years</time_frame>
    <description>lipotoxic genotyping for SNPs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical outcomes of MAFLD vs. non-MAFLD.</measure>
    <time_frame>2 years</time_frame>
    <description>clinical outcomes of MAFLD vs. non-MAFLD.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>training cohort</arm_group_label>
    <description>Consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>validation cohort</arm_group_label>
    <description>For the validation cohort, the clinical and pathological information will be obtained retrospectively by TCOG and will take 6 months to identify eligible patients for the 4 sub-groups listed above.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      next-generation sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hepatocellular carcinoma patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult female or male patients aged â‰¥20 years.&#xD;
&#xD;
          2. HCC has been histologically confirmed with resection specimen.&#xD;
&#xD;
          3. The surgery should be performed with curative intent after 2015 in the study hospital.&#xD;
&#xD;
          4. Availability of serum HBsAg and Anti-HBc data in the electronic medical record.&#xD;
&#xD;
          5. Availability of imaging data performed within 3 months before the surgery in the&#xD;
             electronic medical record. (at least one of the following: computed tomography,&#xD;
             magnetic resonance imaging, abdominal sonography).&#xD;
&#xD;
          6. Informed consent is obtained. Willingness to provide the residual operative slides and&#xD;
             medical records.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fibrolamellar HCC, sarcomatoid HCC, or a mixture of cholangiocarcinoma and HCC&#xD;
&#xD;
          2. Exclusion of HCV patients (Anti-HCV positive)&#xD;
&#xD;
          3. Inability to cooperate by providing a complete medical history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsang-Wu Liu</last_name>
    <role>Study Director</role>
    <affiliation>Taiwan Cooperative Oncology Group, NHRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bor-Rong Chen</last_name>
    <phone>886-2-26534401</phone>
    <phone_ext>25162</phone_ext>
    <email>brong@nhri.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 6, 2022</last_update_submitted>
  <last_update_submitted_qc>November 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>next-generation sequencing</keyword>
  <keyword>precision medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

